Antiviral effects of phosphonoformate (pfa, foscarnet sodium)

Pharmacology and Therapeutics

Volumn 40, Issue 2, 1989, Pages 213-285

  Öberg, Bo ^a  

^a Research and Development at Scania Technical Centre   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; FOSCARNET; RNA DIRECTED DNA POLYMERASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOMEGALOVIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

ADOLESCENT; ADULT; ANIMAL; ANTIVIRAL AGENTS; CHILD; FEMALE; FOSCARNET; GUINEA PIGS; HUMAN; MALE; MICE; NUCLEOTIDYLTRANSFERASES; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHODIESTERASE INHIBITORS; PHOSPHONOACETIC ACID; RABBITS; VIRUS DISEASES; VIRUSES;

EID: 0024555551     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(89)90097-1     Document Type: Review

References (245)

1. Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation
2. Sensitivity of cytomegalovirus to intravenous foscarnet treatment
3. The effect of phosphonoformic acid on wild type and mutant S49 cell lines
4. Selection and characterization of mutant S49 T-lymphoma cell lines resistant to phosphonoformic acid: Evidence for inhibition of ribonucleotide reductace
5. Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds
6. Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs
7. Effect of trisodium phosphonoformate in genital infection of female guinea pigs with herpes simplex virus type 2
8. Therapeutic effect of trisodium phosphonoformate on cutaneous herpesvirus infection in guinea pigs
9. Effect of trisodium phosphonoformate and idoxuridine on experimental herpes simplex keratitis in immunized and non-immunized rabbits
10. Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs
11. Distinctive properties of DNA polymerases induced by herpes simplex virus type-1 and Epstein-Barr virus
12. Foscarnet for cytomegalovirus pneumonitis
13. Complement-fixing antibody to the AG-4 antigen in herpes simplex virus type 2-infected patients
14. Combination chemotherapy: interaction of 5-methoxy-methyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses
15. Efficacy of 5-methoxymethyl-2′-deoxyuridine in combination with arabinosyladenine for the treatment of primary herpes simplex genital infection of mice and guinea pigs
16. Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro
17. Susceptibility of bovid herpesvirus 1 to antiviral drugs: In vitro versus in vivo efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine
18. Utilisation de cellules perméabilisées dans l'etude de produits inhibiteurs de la replication du virus de l'herpes
19. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV)
20. Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo-controlled, multicentre study
21. Susceptibility of phosphonoformic acid-resistant herpes simplex virus variants to arabinosylnucleosides and aphidicolin
22. In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS
23. Disseminating herpes simplex infection: Primary lesions in urinary bladder and successful treatment with foscarnet sodium
24. The antiherpes action of phosphonoacetate
25. Combined chemotherapy of cutaneous herpes simplex infection of the guinea pig
26. Inhibition of vesicular stomatitis virus transcriptase in vitro by phosphonoformate and ara-ATP
27. Comparison of the antiherpetic activity of ACV and PFA in cell cultures and guinea pig skin infection
28. Mode of action of phosphonoformate as an anti-herpes simplex virus agent
29. The inhibition of the RNA polymerase activity of influenza virus A by pyrophosphate analogues
30. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1
31. Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus
32. Genital herpes simplex virus infections: Clinical manifestations, course and complications
33. Comparative studies of interferon and three antiviral agents on neurotropic and oncogenic herpesviruses
34. Mechanism of Epstein-Barr virus replication by phosphonoformic acid
35. Site specific therapy of murine cytomegalovirus lung infection using aerosolized antiviral agents
36. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus
37. Herpes simplex virus type 1 DNA polymerase
38. Characterization of the DNA polymerases induced by a group of herpes simplex virus type 1 variants selected for growth in the presence of phosphonoformic acid
39. Relative potencies of different antiherpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice
40. Synthesis of some phosphonates with antiherpetic activity
41. Inhibition of RNA-dependent DNA polymerase of AIDS and SAIDS retroviruses by HPA-23 (ammonium 21-tungsto-9-antimonate)
42. The selective inhibition of viral DNA synthesis by chemotherapeutic agents: an indicator of clinical usefulness
43. Characteristics of herpesvirus mutants resistant to phosphonoformate and phosphonoacetate
44. Phosphonoformate and phosphonoacetate
45. Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase
46. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin
47. Inhibition of reverse transcriptase activity of avian myeloblastosis virus by pyrophosphate analogues
48. Inhibition of herpesvirus DNA polymerases by foscarnet and related pyrophosphate analogues
49. Different patterns of inhibition of AMV reverse transcriptase activity of 3′-azido-3′-deoxythymidine triphosphate and its threo isomer
50. Pilot study on the treatment of AIDS and ARC patients with intravenous foscarnet
51. The problem of drug-induced resistance in viruses
52. The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs
53. Ion-exchange chromatography with post column reaction for the analysis of phosphonoformate, phosphite and phosphate
54. Mutually exclusive inhibition of herpesvirus DNA polymerase by aphidicolin, phosphonoformate and acyclic nucleoside triphosphates
55. Novel interaction of aphidicolin with herpes simplex virus DNA polymerase and polymerase-associated exonuclease
56. Interaction of DNA polymerase and nucleotide analog triphosphates
57. Nucleic acid hybridization for measurement of effects of antiviral compounds on human cytomegalovirus DNA replication
58. 14C-labelled trisodium phosphonoformate hexahydrate (foscarnet)
59. Sequence and mapping analyses of the herpes simplex virus DNA polymerase gene predict a C-terminal substrate binding domain
60. Human T-cell lymphotropic virus type III shares sequence homology with a family of pathogenic lentiviruses
61. In vitro inhibition of herpesvirus sylvilagus by phosphonoacetic acid and phosphonoformate
62. Characterization of hepatitis B virus DNA polymerase
63. Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans
64. Serum thymidine kinase in transplant patients: Its relation to cytomegalovirus activity, renal transplant rejection and its use for monitoring of antiviral therapy
65. Opportunities for the development and use of antiherpes virus drug combinations
66. Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases
67. Influence of cells and virus multiplicity on the inhibition of herpes viruses with acycloguanosine
68. Multiplicity dependence and sensitivity of herpes simplex virus isolates to antiviral compounds
69. Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells
70. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon
71. Effects of combination antiviral therapy on LAV/HTLV-III replication in vitro
72. The effect of phosphonoacetic acid on herpes viruses
73. Treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection with foscarnet
74. Antiviral screening based on cell-free polymerase models and a new selective inhibitor
75. Enzymatic targets in virus chemotherapy
76. Trisodium phosphonoformate, a new antiviral compound
77. Experimental studies on the antiherpetic agent phosphonoformic acid
78. Antiviral effects of phosphonoformic acid and its derivatives
79. Trisodium phosphonoformate: Antiviral activities, safety evaluation and preliminary clinical results
80. Pyrophosphate analogues as polymerase inhibitors and antiviral agents, with special reference to foscarnet
81. Antiviral activities of pyrophosphate analogues. A new antiherpetic drug, foscarnet
82. Synthesis and antiherpes simplex activity of analogues of phosphonoacetic acid
83. Inhibition of hepatitis-B-virus DNA polymerase by phosphonoformate: Studies on its mode of action
84. Inhibition der Hepatitis-B-virus-spezifischen DNS-Polymerase durch antivirale Substanzen: In vitro-Studien mit klinischer Bedeutung?
85. Foscarnet sodium
86. The biology of hepadnaviruses
87. Genital herpes: Pathogenesis and chemotherapy in the guinea pig model
88. The effect of pyrophosphate analogues on the replication of different strains of influenza virus A in tissue culture
89. The antiviral potential of compounds containing the thiophosphoryl group
90. Thio-analogues of inorganic pyrophosphate inhibit the replication of influenza virus A in vitro
91. Inhibition of viral nucleic acid synthesis by analogues of inorganic pyrophosphate
92. Studies on the biosynthesis of bialaphos (SF-1293). 4. Production of phosphonic acid derivatives, 2-hydroxyethylphosphonic acid, hydroxymethylphosphonic acid and phosphonoformic acid by blocked mutants of Streptomyces hygroscopicus SF-1293 and their roles in the biosynthesis of bialaphos
93. The acquired immunodeficiency syndrome and hypercalcemia
94. Combined interaction of antiherpes substances and interferon B on the multiplication of herpes simplex virus
95. Inhibition of anatid herpesvirus by acyclovir and phosphonoderivatives
96. Design of selective antiviral compounds
97. Baculovirus replication: effects of inhibitors of macromolecular synthesis
98. Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate
99. A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice
100. Phosphonoacetic acid-resistant herpes simplex virus infection in hairless mice
101. Effect of eight antiviral drugs on the reactivation of herpes simplex virus in explant cultures of latently infected mouse trigeminal ganglia
102. Latent infections of sensory ganglia as influenced by phosphonoformate treatment of herpes simplex virus-induced skin infections in hairless mice
103. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients
104. Properties of herpes simplex virus DNA polymerase and characterization of its associated exonuclease activity
105. Physical mapping of drug resistance mutations defines an active center of the herpes simplex virus DNA polymerase enzyme
106. Selection and characterization of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities
107. Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir
108. Selective inhibition of herpesvirus DNA synthesis by foscarnet
109. Selectivity of antiherpes compounds on viral and cellular DNA synthesis
110. Kinetic analysis in cell culture of the reversal of antiherpes activity of nucleoside analogs by thymidine
111. Effect of aphidicolin on DNA synthesis in HSV-1 infected and uninfected Vero cells
112. Deoxythymidine kinase, a possible marker for monitoring activity of cytomegalovirus infections after renal transplantation
113. Effect of phosphonoacetate on Marek's disease virus replication
114. Enrichment of early HSV-induced proteins in phosphonoformate-treated cells
115. Serum antibodies to the major HSV-2-specified DNA-binding protein in patients with an acute HSV infection or cervical neoplasia
116. Ocular manifestations in AIDS
117. Cytomegalovirus retinitis in the acquired immune deficiency syndrome (AIDS). Clinical, angiographic and pathological aspects—treatment with trisodium phosphonoformate (Foscarnet)
118. Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase
119. Characterization of EBV carrying B cell populations in healthy EBV seropositive individuals with regard to density, release of transforming virus and outgrowth
120. Phosphonoformic acid-inhibitable nucleotide incorporation as a measure of hepatitis B viral DNA polymerase activity
121. Micromethod for phosphonoformate inhibition assay of hepatitis B viral DNA polymerase
122. Sensibilidad de 56 aislados de virus herpes simplex de los tipos 1 y 2 en un ensayo ‘in vitro’ frente a fosfonoformiato sodico en células Hep-2
123. Changes in the vaginal cytology of the guinea pig induced by herpes simplex virus
124. Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs
125. Intravenous foscarnet for treatment of severe cytomegalovirus infections in transplant patients
126. Mode of inhibition of herpes simplex virus DNA polymerase by phosphonoacetate
127. Inhibition of DNA polymerase from herpes simplex virus infected Wi-38 cells by phosphonoacetic acid
128. Structure-activity studies on phosphonoacetate
129. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro
130. Phosphonoformate inhibits synthesis of Epstein-Barr virus (EBV) capsid antigen and transformation of human cord blood lymphocytes by EBV
131. Differential inhibition of DNA polymerase and RNAase H activities of the reverse transcriptase by phosphonoformate
132. Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs
133. Foscarnet for cytomegalovirus (CMV) infections in AIDS
134. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III
135. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus in vitro
136. Mechanism of the idling-turnover reaction of the large (Klenow) fragment of Escherichia coli DNA polymerase I
137. Observations on the phosphonoformic acid inhibition of RNA dependent DNA polymerases
138. Inhibition of African swine fever (ASF) virus replication by phosphonoacetic acid
139. In vitro recovery of resistant retrovirus isolates after exposure to phosphonoformate
140. Effect of zinc ions, phosphonoacetate, phosphonoformate and violamycin B I on the induction by herpes simplex virus of chromosome abnormalities in cell cultures
141. 2O
142. Trisodium phosphonoformate inhibits woodchuck hepatitis virus associated DNA polymerase
143. Trisodium phosphonoformate inhibits hepatitis B Dane particle DNA polymerase
144. Inhibition of hepatitis B Dane particle DNA polymerase activity by pyrophosphate analogs
145. No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis production
146. Synthesis of esters of phosphonoformic acid and their antiherpes activity
147. Beitrag zur Kenntnis der organischen Phosphorverbindungen
148. Antiviral effects of phosphonoformate (PFA foscarnet sodium)
149. Inhibitors of virus-specific enzymes
150. Molecular basis of foscarnet action
151. Antiviral chemotherapy against HTLV-III/LAV infections
152. Preclinical evaluation of the herpesvirus inhibitor foscarnet sodium
153. Epstein-Barr virus-specific DNA polymerase in virus-nonproducer Raji cells
154. Properties of herpes simplex virus type 1 and type 2 DNA polymerase
155. Dermatologic diseases
156. Viral-induced leukocyte interferon in vesicle fluid from lesions of recurrent herpes labialis
157. Phosphonoacetic acid
158. Inhibition of herpes simplex virus replication by phosphonoacetic acid
159. Antiviral potential of phosphonoacetic acid
160. Viral Chemotherapy: Antiviral actions of metal ions and metal-chelating agents
161. Cutaneous herpes simplex virus infection of the guinea pig: lack of resistance to acyclovir and phosphonoformic acid after topical treatment
162. Induction of Epstein-Barr virus antigens and DNA-polymerase activities in P3HR-1 cell line and its subline passaged in the presence of phosphonoformate
163. Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds
164. Foscarnet in fulminant hepatitis B
165. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial
166. Inhibition of herpesvirus replication and herpesvirus-induced deoxyribonucleic acid polymerase by phosphonoformate
167. Phosphonoformate inhibition of avian myeloblastosis virus DNA polymerase
168. Foscarnet for cytomegalovirus infections
169. Treatment of life-threatening cytomegalovirus infections with i.v. foscarnet in immuno-compromized patients
170. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients
171. A pilot trial using foscarnet for cytomegalovirus infections in marrow transplant recipients
172. Pharmacokinetics of PFA (trisodium phosphonoformate) after i.v. and p.o. administration to beagle dogs and rabbits
173. The potential of nucleotide analogs as inhibitors of retroviruses and tumors
174. Inorganic pyrophosphate analogs in the pyrophosphorolysis reaction catalyzed by Escherichia coli RNA polymerase
175. The mechanism of pyrophosphorolysis of RNA by RNA polymerase. Endowment of RNA polymerase with artificial exonuclease activity
176. Inhibition of eucaryotic DNA polymerases by phosphonoacetate and phosphonoformate
177. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate
178. Inhibition of HTLV-III/LAV replication by foscarnet
179. Different in vitro effects of dual combinations of antiherpes simplex virus (HSV) compounds
180. Antiviral activity of 5-ethyl-2′-deoxyuridine against herpes simplex viruses in cell culture, mice and guinea pigs
181. Characterization of acyclovirresistant and sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency
182. Resistance of herpes simplex virus to acycloguanosine: the role of viral thymidine kinase and DNA polymerase loci
183. Inhibitory effects of foscarnet on herpesvirus multiplication in cell culture
184. Sensibilité du phosphonoformate de différentes souches du virus de la rhinotrachéite infectieuse bovine (Bovid Herpesvirus 1)
185. Comparison of the effect of trisodium phosphonoformate on the mean plaque size of pseudorabies virus, infectious bovine rhinotracheitis virus and pigeon herpesvirus
186. Susceptibility of different strains of pigeon herpesvirus to trisodium phosphonoformate
187. Effects of antiviral agents on murine cytomegalovirus-induced macrophage dysfunction
188. Foscarnet decreases serum and liver duck hepatitis B virus DNA in chronically infected ducks
189. Susceptibility of several clinical isolates of varicella-zoster virus towards antiherpes drugs
190. Suppression of herpes simplex virus infection by phosphonoacetic acid
191. Foscarnet for cytomegalovirus retinitis
192. Cytomegalovirus retinitis in a renal transplant patient with recurrent opportunist infection: treatment with foscarnet and CMV hyperimmune globulin
193. Synergism among Biolf-62, phosphonoformate and other antiherpetic compounds
194. Effects of acyclovir combined with other antiviral agents on human cytomegalovirus
195. Pathogenesis of herpes simplex labialis. IV. Evolution of lesions during the first 24 hours after onset and implications for antiviral treatment
196. Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection
197. Cellular toxicity of pyrophosphate analogues
198. Reversible effects on cellular metabolism and proliferation by trisodium phosphonoformate
199. Effects of foscarnet on the cell kinetics of Madin-Darby canine kidney cells
200. Concentration-dependent effects of foscarnet on the cell cycle
201. Quantitative analysis of antiviral drug toxicity in proliferating cells
202. Mode of interference of trisodium phosphonoformate (INN: foscarnet sodium), with influenza virus mRNA synthesis
203. The effect of pyrophosphate analogues on influenza virus RNA polymerase and influenza virus multiplication
204. Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid
205. Replication of the genome of hepatitis B-like virus by reverse transcription of an RNA intermediate
206. Phosphonoformate inhibition of visna virus replication
207. Phosphonoformate inhibits reverse transcriptase
208. Inhibition of herpes simplex virus infection in tissue culture by trisodium phosphonoformate
209. Persistent reactivable latent herpes simplex virus infection in trigeminal ganglia of mice treated with antiviral drugs
210. Neuritic uptake and transport of antiviral drugs modifying herpes simplex virus infection of rat sensory neurons
211. +-dependent transport of phosphate across renal brush border membrane
212. Identification and characterization of a DNAase induced by Epstein-Barr virus
213. Antivirale Aktivität von Phosphonoessigsäure, Phosphonopropionsäure und Trinatriumphosphonoformiathexahydrat gegenüber Herpesvirus hominis Typ 1 und Typ 2 in vitro
214. Herpes simplex virus hepatitis in mice: Effects of treatment with trisodium phosphonoformate
215. Evidence for herpes simplex virus type-selective receptors on cellular plasma membranes
216. Multiplicity in activation of herpes simplex virus in mouse neuroblastoma (C1300) cells
217. The effect of topical foscarnet in a new model of herpes simplex skin infection
218. Phosphonoformate selective inhibition of murine retrovirus replication in vitro
219. Inhibition of murine leukemia viruses in vitro by phosphonoformate
220. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from bone marrow transplant patients receiving multiple courses of treatment with acyclovir
221. Inhibition of cytomegalovirus late antigens by phosphonoformate
222. Reversible inhibition of cytomegalovirus replication by phosphonoformate
223. Cytomegalovirus DNA polymerase inhibition and kinetics
224. Computer-based virus sensitivity assay and neutralization method. Applications for herpesviruses
225. A novel method for determining the sensitivity of herpes simplex virus to antiviral compounds
226. i analogs
227. Foscarnet as a drug against cytomegalovirus
228. Treatment of recurrent herpes labialis with trisodium phosphonoformate
229. Foscarnet sodium (trisodium phosphonoformate) in treatment of recurrent herpes infections
230. Foscarnet sodium (trisodium phosphonoformate) in treatment of recurrent herpes infections
231. Topical treatment of recurrent genital herpes in infections with foscarnet
232. Treatment of cytomegalovirus retinitis with trisodium phosphonoformate
233. The acid-catalysed decarboxylation of phosphonoformic acid
234. Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with foscarnet (phosphonoformate)
235. i)
236. Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus
237. Structure-activity relationship of inhibitors of hydroxyapatite formation
238. Assessment of phosphonoformate treatment of pigeon herpesvirus infection in pigeons and budgerigars, and Aujeszky's disease in rabbits
239. PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase
240. Synthese d'analogues tetrazoles de l'acide phosphonoacetique
241. i cotransport by phosphonoformic acid
242. Hypercalcemia and disseminated cytomegalovirus infection in the acquired immunodeficiency syndrome